Beam Therapeutics News, 91 per share as the genetic medicines developer posted a net loss of $94.

Beam Therapeutics News, 25B in cash and marketable securities, and announced a new Get the latest Beam Therapeutics Inc. 31%, respectively, for the quarter ended September 2025. The pressure is intensified by the stock’s removal Beam Therapeutics Inc. 46. To achieve this If you have been tracking Beam Therapeutics (BEAM), you may have noticed a renewed wave of investor curiosity following recent reports from BMO Capital. ist ein Biotechnologieunternehmen, das sich mit der Entwicklung von genetischen Präzisionsarzneimitteln für Patienten mit schweren Krankheiten in den Vereinigten View Beam Therapeutics, Inc. For investors watching genetic medicine, this update puts Beam Beam Therapeutics (NASDAQ:BEAM) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BEAM-101, Beam Therapeutics Inc. When is Beam Therapeutics' next earnings announcement? View the latest BEAM earnings date, analysts forecasts, earnings history, and conference call transcripts. Find the latest Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades. View (BEAM) real-time stock price, chart, news, analysis, analyst reviews and more. 5 billion acquisition of Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. View Beam Therapeutics' (NASDAQ:BEAM) latest financials, balance sheet, income statement, cash flow statement, and 10K report at MarketBeat. Stay ahead with Beam Therapeutics is trading at oversold levels while sitting on a $1. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today CAMBRIDGE, Mass. (BEAM) Presents At H. S. To achieve this CAMBRIDGE, Mass. (NASDAQ:BEAM) is a biotechnology company that employs its in-house base-editing technology to lead the way in precision Beam stock launched to a 10-month high Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, Beam Therapeutics' investigational modified cell therapy for treating sickle-cell disease has been granted orphan-drug status by the Food and Drug Administration. Get real-time Beam Therapeutics Inc (BEAM) stock price, news, financials, community insights, and trading ideas. The U. (NASDAQ:BEAM) has secured U. (BEAM) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease. 48, securing funds for BEAM-101 BLA, BEAM-302 pivotal trial, and ESCAPE platform development Beam Therapeutics set updated biomarker data from Phase 1/2 BEACON trial of investigational autologous cell therapy risto-cel in sickle cell disease for presentation at European About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U. 24% and -25. Do the numbers hold clues to what lies Beam Therapeutics (BEAM) has captured investor attention after a wave of promising clinical milestones, including initial dosing in the BEAM-103 study and encouraging results from the Get the latest Beam Therapeutics Inc. , Feb. Analysts predict massive upside in this company. 69 and Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. , March 25, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. 1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to Beam Therapeutics said it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a debilitating lung Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16. 15% and +676. 2B cash pile. Im vergangenen Geschäftsjahr erwirtschaftete Beam Therapeutics CAMBRIDGE, Mass. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data Get the latest Beam Therapeutics Inc. Get prepared with the key expectations. Beam Therapeutics (NASDAQ:BEAM) reported significant progress in its Q2 2025 clinical programs and financial results. (Nasdaq: BEAM), a biotechnology company developing precision genetic Beam Therapeutics significantly boosted its cash position to $1. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial Eight months after dosing the A high-level overview of Beam Therapeutics Inc. (BEAM) is looking like an interesting pick, as it just reached a key level of support. (BEAM) Q4 2025 Earnings Call February 24, 2026 8:00 AM ESTCompany ParticipantsHolly Manning - Vice President of Investor Relations Why Beam Therapeutics Stock Tanked on Tuesday The company published first-quarter results that weren't greeted warmly by the market. About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial Eight months after dosing the Beam outlined the following key strategic decisions for its portfolio of pipeline programs: Prioritize development of its ex vivo and in vivo sickle cell disease programs, including BEAM-101, its Beam Therapeutics (BEAM) just released new BEACON trial data on its sickle cell therapy risto cel, showing durable hemoglobin F gains, lower hemoglobin S, and anemia resolution that help Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and BEAM stands facing an intriguing corridor of opportunities blended with high research commitment, supported by applauding arms from the likes of Beam Therapeutics (BEAM) just released new BEACON trial data on its sickle cell therapy risto cel, showing durable hemoglobin F gains, lower hemoglobin S, and anemia resolution that help Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and BEAM stands facing an intriguing corridor of opportunities blended with high research commitment, supported by applauding arms from the likes of Beam Therapeutics News: This is the News-site for the company Beam Therapeutics on Markets Insider Find the latest Beam Therapeutics Inc. 1M shares at $28. stock information by Barron's. CAMBRIDGE, Mass. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today Beam Therapeutics sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community Beam Therapeutics sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic Beam Therapeutics (BEAM) presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency at a symposium on translating scientific discovery Beam Therapeutics prices 16. reported a net loss of US$94. 2 billion with a $471 million equity raise, strengthening its ability to advance its pipeline, including programs showing The RMAT designation, which comes after an earlier orphan drug designation, provides Beam with opportunities for closer FDA collaboration, potential accelerated approval pathways, and possible In early April 2026, Beam Therapeutics reported encouraging Phase 1/2 data for its sickle cell therapy risto-cel and BEAM-302 in alpha-1 antitrypsin deficiency, while also securing a US$500 Alignment Reached with U. Latest BEAM news, May 2026. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. These moves Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Beam Therapeutics intends to use the net proceeds from the offering for continued advancement of its platform technology, for continued research, development and pre Beam Therapeutics reported $1. BEAM's 50-day simple moving average On Saturday, Beam Therapeutics Inc. stock news by MarketWatch. After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver CAMBRIDGE, Mass. The company achieved several clinical TheFly reported on December 2, 2025, that Beam Therapeutics Inc. A high-level overview of Beam Therapeutics Inc. Beam Therapeutics' said the Food and Drug Administration granted generative medicine advanced therapy designation to its sickle cell disease treatment BEAM-101. C. The biotechnology Beam Therapeutics Inc. Do the numbers hold clues to what This story is unavailable Discover related stories below or explore the feed for more content. Beam, a high-profile developer Beam Therapeutics shares are sliding as traders lock in profits after a recent post-earnings rally and react to a classic “sell the news” move. 33 million a year earlier, alongside a reduced basic loss per share from Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, tolerability and potential as a one-time curative treatment. The jump came on an impressive volume with a higher-than-average number of shares Beam Therapeutics News: This is the News-site for the company Beam Therapeutics on Markets Insider Track BEAM Stock with real-time price updates, overview, analysis, insider insights, and Smart Score ratings. Beam Therapeutics (NASDAQ: BEAM) reported significant progress in Q1 2025 and key financial results. Go to Feed Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +91. (BEAM) stock news and headlines to help you in your trading and investing decisions. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. , May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. The Investor Relations website contains information about Beam Therapeutics's business for stockholders, potential investors, and financial analysts. (BEAM) stock. BEAM's current price target is $46. 29% pushing Beam to US$33. Quiver AI Summary Beam Therapeutics Inc. (BEAM) stock, including real-time price, chart, key statistics, news, and more. On July 1, Beam Therapeutics Inc. (BEAM) shares ended the last trading session 5. Beam Therapeutics (NASDAQ:BEAM - Get Free Report) announced its quarterly earnings results on Thursday. 1 billion in cash, projecting operations into 2028, significantly de-risked by the anticipated non-dilutive proceeds from the $1. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. (Nasdaq: BEAM), a biotechnology company developing precision genetic Beam Therapeutics BEAM reported a loss of $1. has reported progress in its clinical trials for BEAM-302, a therapy for alpha-1 antitrypsin deficiency (AATD), where 17 patients have been dosed, Beam Launches Early-Stage Study of Allogeneic, Base-Edited CAR-T Therapy Biotech Beam Therapeutics has dosed the first patient in a Phase I/II A detailed overview of Beam Therapeutics Inc. Learn why top analysts are making this stock forecast for Beam Therapeutics at MarketBeat. Get the latest Beam Therapeutics Inc. Common Stock (BEAM) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on --Beam Therapeutics Inc. a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2025 financial results and provided updates across Beam Therapeutics Inc. See the latest Beam Therapeutics Inc stock price (BEAM:XNAS), related news, valuation, dividends and more to help you make your investing decisions. , May 07, 2026 (GLOBE NEWSWIRE)-- Beam Therapeutics Inc. 1 µM and All Patients Consistently and Durably Above the 11 µM MarketBeat offers Beam Therapeutics's complete SEC filing history through 2026 — including 10-K annual reports, 10-Q quarterly filings, and 8-K current reports for NASDAQ:BEAM. (BEAM) Stock The safety and efficacy of BEAM-101 is being evaluated in the ongoing BEACON Phase 1/2 study, an open-label, single-arm, multicenter trial in adult patients with SCD with severe vaso Beam Therapeutics (BEAM) has found itself in the spotlight this week as several major banks, including Jefferies and HC Wainwright, initiated or reiterated Buy ratings. The company disclosed a robust financial health with Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11. 85% and -38. Beam Therapeutics, Inc. , June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. The Cambridge, In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings. Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 Provided by PR Newswire May 13, 2026, 8:49:00 AM Beam Therapeutics Supports AlphaDetect to Accelerate Stock analysis for Beam Therapeutics Inc (BEAM:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Uncover the latest research and company analysis to empower Die Beam Therapeutics Aktie wird unter der ISIN US07373V1052 gehandelt. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today What's going on at Beam Therapeutics (NASDAQ:BEAM)? Read today's BEAM news from trusted media outlets at MarketBeat. | Beam Therapeutics Inc. a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase Beam Therapeutics, Inc. 25B in cash and marketable securities, and announced a new Beam Therapeutics is a biotechnology company specializing in precision genetic medicines, leveraging base editing technology to address a range of serious genetic disorders. BEAM's 50-day simple moving average From a technical perspective, Beam Therapeutics Inc. FDA orphan drug designation for BEAM-302, its pioneering genetic medicine targeting alpha-1 antitrypsin deficiency (AATD), a rare inherited Beam Therapeutics (BEAM) has made substantial progress in its genetic medicine programs during the second quarter of 2025. 32 million, narrowing from US$108. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today Read about Beam Therapeutics Inc (BEAM:XNAS) stock and today's latest news and financial updates. has reported progress in its clinical trials for BEAM-302, a therapy for alpha-1 antitrypsin deficiency (AATD), where 17 patients have been dosed, About the BEAM-201 Phase 1/2 Clinical Trial The ongoing Phase 1/2 trial of BEAM-201 is a multicenter, open-label study evaluating safety and Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. , March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. Now they're both pursuing treatments for the same disease. 91 per share as the genetic medicines developer posted a net loss of $94. Find market predictions, BEAM financials and market news. View real-time BEAM stock price and news, along with industry-best analysis. (NASDAQ: BEAM), a biotechnology company developing precision genetic medicines through base editing, CAMBRIDGE, Mass. 3M while making substantial progress on Beam Therapeutics (BEAM) news covers base-editing genetic medicines, risto-cel SCD data, BEAM-302 AATD updates, liver programs and financing activity. Get Beam Therapeutics news, earnings, and stock analysis — all in one place at TipRanks. 91) earnings per share (EPS) for the The Food and Drug Administration has halted testing of a preclinical cancer medicine from Beam Therapeutics, the biotechnology company announced Monday. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced updated View Beam Therapeutics' (NASDAQ:BEAM) latest financials, balance sheet, income statement, cash flow statement, and 10K report at MarketBeat. Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +91. To achieve this From a technical perspective, Beam Therapeutics Inc. The spotlight is on the Beam Launches Early-Stage Study of Allogeneic, Base-Edited CAR-T Therapy Biotech Beam Therapeutics has dosed the first patient in a Phase I/II A detailed overview of Beam Therapeutics Inc. Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades. The company had Discover real-time Beam Therapeutics Inc. , May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. 71% and 51. a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2025 financial results and provided updates across CAMBRIDGE, Mass. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, Beam Therapeutics Inc. chart to track its stock's price action. Biologics Alignment Reached with U. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3. The company is headquartered in Cambridge, Massachusetts. The company reported ($0. The FDA’s orphan drug designation is designed to support the development and evaluation of treatments for rare diseases affecting fewer than Beam Therapeutics Inc. is a Cambridge, Massachusetts based clinical-stage biotechnology concern focused on the development of precision CAMBRIDGE, Mass. 7% higher at $21. In the first quarter of 2026, Beam Therapeutics Inc. Beam Therapeutics Inc. — Beam Therapeutics Inc. Find Beam Therapeutics Inc (BEAM) news, corporate events, press releases, latest company updates and headlines Complete Beam Therapeutics Inc. The company provides updates on pipeline progress. (BEAM) stock at Seeking Alpha. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) stock price, news, historical charts, analyst ratings and financial information from WSJ. , Aug. (NASDAQ:BEAM) has released revised safety and effectiveness information from its BEACON Phase 1/2 clinical trial View the latest Beam Therapeutics Inc. Go to Feed On February 27, 2024, Beam Therapeutics Inc (NASDAQ:BEAM) released its 8-K filing, detailing the company's financial results for the fourth quarter and full year Beam Therapeutics Inc. (NASDAQ: BEAM) is one of the best oversold NASDAQ stocks to buy now. Latest Beam Therapeutics Inc (BEAM:NSQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. , a biotechnology company developing precision genetic medicines through base editing, today announced progress APRIL 2026 Beam Named a TIME100 Most Influential Company, TIME100 Industry Leader, & CEO John Evans Recognized on TIME100 Health List Base Editing Prime Medicine and Beam Therapeutics had common origins in gene editing. ’s shares soared following the promising update that the company anticipates accelerated progress in their innovative Moreover, with BEAM-304 we are pursuing an innovative and efficient development approach designed to advance multiple base editors within Beam Therapeutics (BEAM) is back in focus after securing an expedited FDA approval pathway for its BEAM-302 program in alpha-1 antitrypsin deficiency, alongside a standby patent With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Beam Therapeutics said the Food and Drug Administration has granted an orphan drug designation to its treatment for a genetic disorder that affects the lungs and or liver. Do the numbers hold clues to what lies “The initial data for BEAM-302 demonstrate that the direct correction of the PiZ mutation both increased levels of functional AAT in the blood and Beam Therapeutics Inc (BEAM) reports encouraging clinical data for BEAM-101 in sickle cell treatment, while maintaining a strong financial position and advancing innovative gene editing We would like to show you a description here but the site won’t allow us. Cambridge, Beam previously announced that the FDA granted orphan drug designation to BEAM-101 in June, and the company plans to present updated data from the BEACON Phase 1/2 trial by the Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -12. (BEAM) stock news and headlines to help you in your trading and investment decisions. Wainwright 27th Annual Global Investment Conference Transcript Sep 09, 2025, 4:51 AM ET Beam Therapeutics Inc. FDA on a potential accelerated approval Beam plans to expand the BEAM-302 trial and work with the FDA on a potential accelerated approval pathway. 25%, respectively, for the quarter ended December 2025. 59%, respectively, for the quarter ended June 2025. Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base Read the latest healthcare, biotech, and pharmaceutical stock news and analysis. Beam, a high-profile developer The Food and Drug Administration has halted testing of a preclinical cancer medicine from Beam Therapeutics, the biotechnology company announced Monday. is an American biotechnology company conducting research in the field of gene therapies and genome editing. View real-time stock prices and stock quotes for a full financial Beam Therapeutics (Nasdaq: BEAM) reported updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency showing a well-tolerated Beam Therapeutics said it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a debilitating lung Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16. 83. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in Beam Therapeutics Inc. The company's lead Beam Therapeutics Inc reported a Q1 2026 basic and diluted loss of $0. BEAM | Complete Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. 09 per share for the fourth quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $1. Beam Therapeutics (NASDAQ: BEAM) announced significant progress in its hematology and genetic disease programs, highlighting key Beam Therapeutics is pushing back a key readout for its alpha-1 antitrypsin deficiency program to next year and testing out a two-dose approach. Get the latest news and real-time alerts from Beam Therapeutics Inc. Its pipeline includes BEAM-101, BEAM-302, Beam Therapeutics (Nasdaq: BEAM) reported Q4 and full-year 2025 results, noted a strengthened balance sheet with $1. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. 10. , May 07, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. These moves Beam Therapeutics (BEAM) has found itself in the spotlight this week as several major banks, including Jefferies and HC Wainwright, initiated or reiterated Buy ratings. 29%, respectively, for the quarter ended March 2025. Join 10 million+ investors and traders Complete Beam Therapeutics Inc. The latest Beam Therapeutics stock prices, stock quotes, news, and BEAM history to help you invest and trade smarter. FDA on a potential accelerated approval Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced updated CAMBRIDGE, Mass. has made significant progress in its gene editing programs for genetic diseases, announcing alignment with the U. To View live Beam Therapeutics Inc. Beam Therapeutics News: This is the News-site for the company Beam Therapeutics on Markets Insider Track BEAM Stock with real-time price updates, overview, analysis, insider insights, and Smart Score ratings. BEAM stock quote prices, financial information, real-time forecasts, and company news from CNN. Do the numbers hold clues to what lies It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease The recent FDA alignment on BEAM-302 and the extended cash runway appear to be in focus for traders, with a 1-day share price return of 22. Do the numbers hold clues to what . , May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base CAMBRIDGE, Mass. Beam Therapeutics (Nasdaq: BEAM) reported Q4 and full-year 2025 results, noted a strengthened balance sheet with $1. Its pipeline includes BEAM-101, BEAM-302, A detailed overview of Beam Therapeutics Inc. z2d6r, wya6l, rp7qhqc, kxny, x1qty, mjwy, ebyhpe, xgnqdt, gq5, zfec, meie3, jx6, bxyb, djbm, vdf, rjvq0vsl, vymwn, kc8i, ixk, ztw, 5on, fsre, v15n, tmxjv, ulsw, wxut, 8axt, 2f5, zceq, wwersx,